14 July 2021
Visiongain has published a new report entitled the Pharma Contract Sales Market Report 2021-2031: Forecasts by Type (Personal Promotion (Standard Field Force Roles, Sales Deployment, Vacancy Coverage, HCP Educational Programs, Key Account Management, Other), Non-Personal Promotion (Contact Center, Teledetailing, Medical Call Centers, Telesampling, Online Services), Co-Promotion (Marketing Research and Consulting, Product Commercialization, Territory Optimization & Alignment, Brand Management, Mature Product Line Support, Rest All CSO Services)), by Theraputic (Cardiovascular Disease, Metabolic Disorders, Oncology, Alzheimer's Disease, Diabetes, Other) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Pharma Contract Sales Companies AND COVID-19 Recovery Scenarios.
The global Pharma Contract Sales market was valued at US$xx million in 2020 and is projected to grow at a CAGR of xx% during the forecast period 2021-2031. Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers' operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
How has COVID-19 had a significant negative impact on the Pharma Contract Sales Market?
This COVID-19 related shortage also affected the health market for medical devices and personal protective equipment (PPE), which includes protective goggles and visors, mouth-nose protection equipment, and protective clothing and gloves, that made countries to legislate regulations in this regards. The market entry facilitation and export restrictions of PPE and selected medical devices European Commission (2020/403 of 13 March 2020) is one example, in global levels
How this Report Will Benefit you?
Visiongain’s 520+ page report provides 331 tables and 311 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the global pharma contract sales market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for Pharma Contract Sales. Get the financial analysis of the overall market and different segments including type, Personal Promotion, Non-Personal Promotion, Co-Promotion, therapeutic and capture higher market share. We believe that high opportunity remains in this fast-growing pharma contract sales market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report would help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.
What are the current market drivers?
Inclination Of Pharma Companies Towards Contract Sales To Gain A Competitive Edge
The pharma services industry is consolidating as companies aim to gain a competitive edge over their competitors by increasing size, expanding geographical reach, and achieving synergies. Recent M&A in the sub-sector motivated by pharma's desire to work with less outsourced service providers, as well as a desire to consolidate but also broaden service portfolios outside of conventional CSO services into complementary adjacent fields. Ashfield's entrance into the commercialisation consulting and marketing industries is an example of this.
The Pharma Contract Sales Is "All-In-One" Solution
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers' operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use. For example, The Apodi Healthcare is providing wide range of solutions such as for human-centred, requiring the deployment of promotional resources and/or healthcare professionals, and are often aided by cutting-edge technology. Their services are mainly focused on educating and promoting particular drugs to healthcare professionals, as well as providing patient programmes that help their strategies make a real difference by improving patients' lives, funding the NHS, and generating revenue for their clients.
Where are the market opportunities?
Outsourcing Is Becoming More Common Due to Pressures from The Pharmaceutical Industry
Although attractive as the pharmaceutical industry's fundamental principles remain, the increased cost of R&D and continuing strain on the operating margins of pharmaceutical companies has encouraged the industry to out-source its non-core operations and streamline its fixed cost bases. The industry is expected to continue to expand its medium-term pressures combined with considerable headroom in today's outsourcing penetration. While the market size of clinical research organisations (CRO-conducted clinical development) was $36.7 billion in to 2020.
Increased Interest In CRO Services Fuelled By Data
Data and analytics are becoming increasingly crucial for the provision of CRO services. M&A objectives have in recent years been set by a number of organisations specialising in these areas. Big data utilisation in testing is quickly rising and has increased the quality of data collecting so that larger data sets can be analysed better. For Example, in 2020 the eight major European markets, EON has chosen a Publicis Groupe Power of One solution led by Starcom as its media partner.
The major players operating in the pharma contract sales market are Apodi Healthcare Limited, CMIC Holdings Co., Ltd, Syneos Health Inc., IQVIA Holdings Inc., Marvecs GmbH, OnCall LLC, Publicis Groupe SA, Sofip, UDG Healthcare PLC, Amplity Health, Granard Pharmaceuticals, Vanguard Pharma, GTS Solution, MaBiCo (Contract Sales Organization), Sales Partnerships Inc., QFR Solutions. These major players operating in this market have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new product launch. For instance, in Nov 2020, Mondelez International extended its partnership with Publicis Groupe to cover all production duties across Europe as part of its journey to develop a transformative end-to-end consumer experience. With its integrated creative, media, and development capabilities, Publicis Groupe will create a transformative and seamless consumer experience for Mondelz International brands such as Cadbury, OREO, Milka, LU, Trident, Philadelphia, and RITZ.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.
21 September 2022
The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.
16 September 2022
The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.
15 September 2022
The medical device contract manufacturing market was valued at US$69.22 billion in 2021 and is projected to grow at a CAGR of 12.9% during the forecast period 2022-2032.